Thyrocare's Q2 revenue rises 25% to ₹270.8 crore; ₹45 crore impairment on NHL sale

What happened

• Investywise gave consolidated revenue as ₹270.8 crore, up 25.1% on a year earlier, and EBITDA as ₹89.3 crore, up 24.9%. Profit after tax before exceptional items was ₹60.2 crore, up 25.7%.
• Investywise said the results include a one-time, non-cash impairment charge of ₹45 crore tied to the sale of the NHL business. Whalesbook gave the charge as ₹44.98 crore against the subsidiary Nueclear Healthcare Limited.
• Whalesbook reported net profit of ₹15.22 crore against ₹47.81 crore, and said the company plans to divest NHL for ₹141.40 crore, in cash and compulsorily convertible preference shares.
• The company processed 61.6 million tests in the quarter, up 27.4%, per Investywise. First-half revenue was ₹510.8 crore, up 24.7%, with EBITDA of ₹166.6 crore, up 29.2%.

Why it matters

The two outlets report different profit measures. Investywise gave the figure before exceptional items, ₹60.2 crore, and Whalesbook the net profit after the impairment, ₹15.22 crore. Both carry the same revenue. The results were published on Thursday afternoon (Whalesbook at 3:55 PM), before Thursday's evening edition was written, and were not in it.

Good to know: An impairment charge writes down the value an asset is carried at on a company's books. It reduces reported profit but involves no cash leaving the company, which is why it is called non-cash.

Key facts

Consolidated revenue

₹270.8 crore, up 25.1% (YoY)

EBITDA, per Investywise

₹89.3 crore, up 24.9%

PAT before exceptional items, per Investywise

₹60.2 crore, up 25.7%

Net profit, per Whalesbook

₹15.22 crore (₹47.81 crore)

Impairment on NHL

₹45 crore (Investywise); ₹44.98 crore (Whalesbook)

Read the source

• Thyrocare: Q2 FY27 Revenue Jumps 25.1% to ₹270.8 CroreInvestywise
• Thyrocare Q2 Profit Dips to Rs 15.22 Crore; Eyes Nueclear DivestmentWhalesbook